

Aerocrine

Press release
9 January 2008

Aerocrine strengthens its patent portfolio

SOLNA – 9 January 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has strengthened its patent portfolio by both acquiring a strategically important patent and patenting its own discoveries.

Aerocrine has acquired a patent that describes how to electronically control the flow of exhaled air when measuring nitric oxide. Repeated exhalation with different airflows allows airway inflammation to be localized peripherally or centrally. This could be highly significant both for diagnosis and when choosing medication for patients with asthma-like symptoms, and in cases of suspected COPD. The discovery comes from a Finnish research group led by Professor Eeva Moilanen and Dr Lauri Lehtimäki Medical School, University of Tampere. Electronically controlling the flow of exhaled air enables quick and controlled measurements. Aerocrine uses this new technology in its latest product, NIOX[®] Flex.

Over the past year, the company also gained approval in the US for the first patent in a completely new patent family. This patent involves a way of measuring whether patients who have undergone polyp surgery have improved nasal flow through.

An early focus on patents from Aerocrine's founders provides the foundation for the company's broad patent portfolio. The company's patents are distributed over three business areas and 13 separate patent families. Continuous technological development with a clear patent focus is a critical part of the company's long-term strategy.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82

About Aerocrine

Aerocrine AB (publ) is a medical technology concern focused on the improved management and care of patients with airway inflammation. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007. The company markets NIOX[®] Flex globally, and also markets NIOX MINO[®] – which represents a new generation of hand-held products – in Europe. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of asthma patients. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK.